 Home > Biochemistry News > Biotechnology News > Gene editing makes "ready-to-use" CAR-T therapy Phase 1 clinical trial results are positive

Gene editing makes "ready-to-use" CAR-T therapy Phase 1 clinical trial results are positive

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

phase contrast imaging

vesicles picture

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, CRISPR Therapeutics announced that the allogeneic CAR-T cell therapy CTX110, modified by CRISPR gene editing technology, has obtained positive safety and efficacy results in a phase 1 clinical trial for the treatment of CD19-positive B-cell cancers

CTX110 is an allogeneic CAR-T cell therapy manufactured using CRISPR gene editing technology

▲Introduction of CTX110 (picture source: CRISPR Therapeutics)

In this clinical trial, a total of 26 large B-cell lymphoma patients received CTX110 treatment and were followed up for at least 28 days

▲Efficacy data of phase 1 clinical trial of CTX110 (picture source: reference [1])

After 6 months of treatment, the complete remission rate was 21%, and the longest remission lasted more than 18 months, showing the potential of CTX110 to bring sustained remission

In terms of safety, CTX110 shows differentiated positive safety features

Only one patient with HHV-6 encephalitis developed immune effector cell-related neurotoxicity syndrome (ICANS) above grade 3

Picture source: reference [1]

Reference materials:

[1] CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.